Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01159600 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,504
- Enrollment target
NCT01159600 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,504 participants.
The verdict
NCT01159600, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,504 participants
- Enrollment target
Study Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.
Interventions
- DRUG BI 10773
- DRUG Placebo identical to BI 10773 high dose
- DRUG Placebo identical to BI 10773 low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,504 participants |
| Start Date | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01159600
The ClinicalTrials.gov registry entry for NCT01159600 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BI 10773 is the first listed.
NCT01159600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01159600 about?
NCT01159600 is a clinical study titled "Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes". The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.
What is the current status of trial NCT01159600?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,504 participants. The study started on 2010-07.
What interventions are being tested in trial NCT01159600?
The interventions under investigation include: BI 10773 (DRUG), Placebo identical to BI 10773 high dose (DRUG), Placebo identical to BI 10773 low dose (DRUG).
Who is sponsoring clinical trial NCT01159600?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.